Protagonist Therapeutics, Inc.
NASDAQ:PTGX
45.62 (USD) • At close April 29, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 434.433 | 60 | 26.581 | 27.357 | 28.628 | 0.231 | 30.925 | 20.063 | 0 | 0 | 0 |
| Cost of Revenue
| 0 | 0 | 1.032 | 2.775 | 0 | 0 | 0 | 0 | 0.317 | 0.247 | 0 |
| Gross Profit
| 434.433 | 60 | 25.549 | 24.582 | 28.628 | 0.231 | 30.925 | 20.063 | -0.317 | -0.247 | 0 |
| Gross Profit Ratio
| 1 | 1 | 0.961 | 0.899 | 1 | 1 | 1 | 1 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 138.128 | 120.161 | 126.215 | 126.006 | 74.506 | 65.003 | 59.497 | 46.181 | 25.705 | 11.831 | 7.459 |
| General & Administrative Expenses
| 43.462 | 33.491 | 31.739 | 27.196 | 18.638 | 15.749 | 13.697 | 11.779 | 6.961 | 2.963 | 1.86 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 43.462 | 33.491 | 31.739 | 27.196 | 18.638 | 15.749 | 13.697 | 11.779 | 6.961 | 2.963 | 1.86 |
| Other Expenses
| 0 | 0 | -0.08 | -0.149 | -0.046 | -0.001 | 0 | 0 | -0.034 | 0 | 0 |
| Operating Expenses
| 181.59 | 153.652 | 157.954 | 153.202 | 93.144 | 80.752 | 73.194 | 57.96 | 32.666 | 14.794 | 9.319 |
| Operating Income
| 252.843 | -93.652 | -131.373 | -125.845 | -64.516 | -80.521 | -42.269 | -37.897 | -32.666 | -14.794 | -9.319 |
| Operating Income Ratio
| 0.582 | -1.561 | -4.942 | -4.6 | -2.254 | -348.576 | -1.367 | -1.889 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| 26.565 | 14.697 | 3.98 | 0.294 | -0.329 | 2.643 | 2.546 | 0.94 | -4.511 | -0.064 | -1.753 |
| Income Before Tax
| 279.408 | -78.955 | -127.393 | -125.551 | -64.845 | -77.878 | -39.723 | -36.957 | -37.177 | -14.858 | -11.072 |
| Income Before Tax Ratio
| 0.643 | -1.316 | -4.793 | -4.589 | -2.265 | -337.134 | -1.284 | -1.842 | 0 | 0 | 0 |
| Income Tax Expense
| 4.22 | 0 | -3.98 | -2.924 | 1.305 | -0.691 | -0.799 | -0.406 | 4.16 | 0.064 | 1.753 |
| Net Income
| 275.188 | -78.955 | -123.413 | -122.627 | -66.15 | -77.187 | -38.924 | -36.957 | -37.177 | -14.858 | -11.072 |
| Net Income Ratio
| 0.633 | -1.316 | -4.643 | -4.482 | -2.311 | -334.143 | -1.259 | -1.842 | 0 | 0 | 0 |
| EPS
| 4.47 | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
| EPS Diluted
| 4.23 | -1.39 | -2.52 | -2.65 | -1.92 | -2.98 | -1.74 | -2.09 | -5.72 | -2.52 | -1.88 |
| EBITDA
| 252.843 | -90.34 | -131.373 | -123.07 | -63.662 | -78.306 | -39.196 | -36.551 | -32.349 | -14.547 | -9.061 |
| EBITDA Ratio
| 0.582 | -1.506 | -4.942 | -4.499 | -2.224 | -338.987 | -1.267 | -1.822 | 0 | 0 | 0 |